Shattuck Labs Inc. (STTK)
1.17
0.05 (4.46%)
At close: Jan 15, 2025, 9:51 AM
undefined% (undefined)
| Bid | 1.15 |
| Market Cap | 55.86M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.53 |
| PE Ratio (ttm) | -0.76 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 1.18 |
| Volume | 4,153 |
| Avg. Volume (20D) | 303,800 |
| Open | 1.17 |
| Previous Close | 1.12 |
| Day's Range | 1.16 - 1.22 |
| 52-Week Range | 0.94 - 11.76 |
| Beta | undefined |
About STTK
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorpor...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 9, 2020
Employees 75
Stock Exchange NASDAQ
Ticker Symbol STTK
Website https://www.shattucklabs.com
Analyst Forecast
According to 3 analyst ratings, the average rating for STTK stock is "Hold." The 12-month stock price forecast is $2, which is an increase of 70.94% from the latest price.
Buy 0.00%
Hold 100.00%
Sell 0.00%
Next Earnings Release
Shattuck Labs Inc. is scheduled to release its earnings on Feb 27, 2025,
during market hours.
Analysts project revenue of $999.25K, reflecting a 39.95% YoY growth and earnings per share of -0.32, making a -21.95% decrease YoY.
Analysts project revenue of $999.25K, reflecting a 39.95% YoY growth and earnings per share of -0.32, making a -21.95% decrease YoY.
2 months ago ·
Source
+12.3%
Shattuck Labs shares are trading higher after the ...
Unlock content with
Pro Subscription
3 months ago ·
Source
-34.9%
Shattuck Labs shares are trading lower after Needham downgraded the stock from Buy to Hold. Also, Citigroup downgraded the stock form Buy to Neutral and lowered its price target from $8 to $2.
